Global HIV Diagnostics and Therapeutics Markets Report 2023-2028 with Competitive Analysis of Medtronic, Abbott, Sanofi, Roche, Bio-Rad Laboratories, and Danaher - ResearchAndMarkets.com

The "Diagnostics and Therapeutics for HIV: Global Markets" report has been added to ResearchAndMarkets.com's offering.

The global market for diagnostics and therapeutics for HIV was valued at $28.8 billion in 2022. This market is forecast to grow at a compound annual growth rate (CAGR) of 5.3% to reach $39.3 billion in 2028.

The global HIV therapeutics market is poised for significant growth, with a focus on various drug classes. These include nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), single tablet regimen fixed-dose combinations (STR FDC), HIV integrase strand transfer inhibitors (INSTIs), and non-nucleoside reverse transcriptase inhibitors (NNRTIs). Notably, the report excludes the enzyme inhibitor drug class due to a lack of late-stage pipeline molecules.

Within this landscape, the single-tablet regimen FDC segment stands out, commanding a substantial 37.2% market share. This dominance can be attributed to its status as the preferred therapy for HIV treatment, driven by enhanced patient compliance. Fixed-dose combinations are gaining popularity as they reduce dosing errors and minimize the risk of drug-resistant HIV strains. Looking ahead to 2028, NRTIs are expected to claim a 29.0% market share, equivalent to a $11.0 billion valuation, as they constitute the foundational component of antiretroviral therapy.

The report also delves into diagnostic tests, encompassing antigen-and antibody-based tests, CD4 tests, and viral load tests, with a particular focus on enzyme-linked immunosorbent assay (ELISA) tests, enzyme immunoassay (EIA) tests, rapid tests, and nucleic acid testing (NAT) tests. CD4 tests are crucial for monitoring CD4 load, while viral load tests include various polymerase chain reaction (PCR)-based tests.

In the battle against HIV/AIDS, effective antiretroviral treatment has extended its reach to developing nations, making diagnostics and prevention methods paramount in curbing the epidemic. Key strategies include early diagnosis, rapid initiation of antiretroviral therapy (ART), and viral load monitoring. Nonetheless, the enduring challenge lies in addressing the long-term adverse effects of therapeutic drugs and their efficacy against drug-resistant HIV strains.

The report offers an in-depth analysis of market dynamics and structure, incorporating a Porter's Five Forces analysis and insights into the supply and distribution chain. It covers current regulations and guidelines for HIV diagnostics and therapeutics, presenting a survey of leading market players.

These players' business operations, segment focus, revenue, and strategy analysis are detailed, along with a market share analysis that encompasses product launches and pipeline products.

Report Includes

• An estimate of the market's size and analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Quantification of the market potential of diagnostics and therapeutics for HIV by drug category, diagnostic test type, and region
• Coverage of HIV timeline and milestones, HIV life cycle, its treatment and mechanism of action, and description of HIV prophylaxis
• Evaluation of market dynamics such as drivers and restraints, current industry trends and patterns, and an assessment of the cost implications for treatments in many countries
• Information on regional awareness programs, WHO initiatives and development of novel therapies, and discussion on rising comorbidities in HIV patients and social stigma associated with STDs
• Coverage of ongoing research and predictions of the market's future direction
• Insights into the regulatory scenario for the U.S., Europe and Japan, to provide an overview of the regulations for new drug launches and diagnostic kits
• Descriptions of the competitive landscape, product mapping, the strategic initiatives of the leading companies, including their R&D activities
• Profiles of the key companies, including Medtronic, Abbott, Sanofi, Roche, Bio-Rad Laboratories Inc., and Danaher Corp.

Key Attributes:

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

• Overview
• Market Outlook

Chapter 3 Market and Technology Background

• Overview of Human Immunodeficiency Virus (HIV)
• Report Overview
• Disease Prognosis
• Symptoms
• Treatments
• HIV Timeline and Milestones
• HIV Life Cycle: Treatment and Mechanism of Action
• HIV Prophylaxis
• Pre-Exposure Prophylaxis (Prep)
• Post-Exposure Prophylaxis (Pep)
• Drug Resistance
• Medication Adherence
• Who Initiatives

Chapter 4 Global Industry Trends

• Trends in Global HIV Transmission
• Regional Awareness Programs
• Development of Novel Therapies
• Public-Private Partnerships
• Rising Comorbidities in HIV Patients With An Increase in the Longevity of Patients
• Global Programs to Counter HIV
• Preventing Transmission from Mother to Child
• Challenges
• Underestimating the Risk of Contracting the Disease
• Social Stigma Associated With STDs
• High Cost of Treatment

Chapter 5 Market Breakdown by HIV Therapeutic

• Global Market Forecast for HIV Therapeutics
• Regional Markets for HIV Therapeutics
• North America
• Market Analysis and Forecast
• Epidemiology
• HIV Testing and Recommendations
• Regulation of the North American Market for HIV Therapeutics
• European Market for HIV Therapeutics
• Market Analysis and Forecast
• Epidemiology
• HIV Testing and Recommendations
• Regulations Impacting the European HIV Market
• Asia-Pacific Market for HIV Therapeutics
• Southeast Asian Regions
• Western Pacific Regions
• Prevention and Screening Programs
• Regulation of the Asia-Pacific HIV Market
• Market Impact of Generic Manufacturers
• Market Analysis and Forecast
• Rest of the World (Row) Market for HIV Therapeutics
• African Region
• Global Investments in the HIV Market

Chapter 6 HIV Market by Arv Drug Category

• Overview
• Timeline of Therapies
• First-Line Treatment Regimen
• Second-Line Treatment Regimen
• Third-Line/Salvage Treatment Regimen
• Market Overview by Drug Category
• Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (Nrtis)
• Protease Inhibitors (Pis)
• Single-Tablet Regimen (Str)/Fixed-Dose Combination (Fdc) Drugs
• Integrase Strand Transfer Inhibitors (Insti)
• Non-Nucleotide Reverse Transcriptase Inhibitors (Nnrtis)
• Entry Inhibitors

Chapter 7 Emerging Technologies

• Overview
• Molecular Diagnostics
• Next-Generation Sequencing (Ngs)
• Point-Of-Care Testing
• Artificial Intelligence (Ai)
• Other Emerging Techniques

Chapter 8 Evaluation of Market for Hiv Diagnostics

• Market for Hiv Diagnostics by Test Type
• Evolution of Hiv Tests
• Antigen- and Antibody-Based Tests
• Future Perspective
• Cd4 Testing
• Viral Load Testing
• Hiv Diagnostic Product Profiles by Test Type
• Cd4 Testing Products
• Viral Load Testing Products

Chapter 9 Patents

• Overview

Chapter 10 Competitive Landscape

• Mergers, Acquisitions and Collaborations

Chapter 11 Company Profiles

• Abbott
• Astrazeneca
• B. Braun Se
• Becton, Dickinson and Company
• Biocon
• Bio-Rad Laboratories Inc.
• Boehringer Ingelheim International GmbH
• Danaher Corp.
• Dexcom Inc.
• Insulet Corp.
• Johnson & Johnson Services Inc.
• Lifescan Ip Holdings LLC
• Lilly
• Medtronic
• Merck & Co. Inc.
• Nova Biomedical
• Novartis AG
• Novo Nordisk A/S
• Qiagen N.V.
• Roche (F. Hoffmann-La Roche Ltd.)
• Sanofi
• Siemens Healthineers AG
• Terumo Corp.
• Thermo Fisher Scientific Inc.
• Ypsomed Ag

For more information about this report visit https://www.researchandmarkets.com/r/8qj4ao

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231113902193/en/